Adverse outcomes increased with long-term inhaled corticosteroids in COPD
For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...
Medindia6d
Inhaled Corticosteroids for Lung Disease: Relief Today, Risk Tomorrow
Long-term inhaled corticosteroid (ICS) use for chronic obstructive pulmonary disease/ COPD (lung disease) may increase the ...
GlobalData on MSN6d
EMA to review GSK’s Nucala for COPD treatment expansion
GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...
News-Medical.Net on MSN6d
Long-term inhaled corticosteroids linked to increased health risks in COPD patients
Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...
Pharmabiz2d
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in ...
Sanofi: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu ...
Pharmabiz5d
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment
EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...